A brief overview of the structural features of remodeling that occurs in the sinuses is provided in Table 1. The exact details of these features are not the subject of this review and are discussed elsewhere. The aim of this article is to review the potential clinical implications of remodeling in the sinuses, which revolve around the probable (or improbable) reversibility of these structural modifications with various therapies.
To discuss the subject of reversibility in remodeled mucosa, the complex relationship between remodeling and inflammation warrants review.
Traditionally, remodeling is viewed as a secondary process that occurs due to a longstanding inflammatory process, which culminates in increased ECM deposition, basement membrane thickening, and irreversibly remodeled mucosa. This theory of irreversible mucosal changes in the airway has been recently challenged, primarily in the asthma literature, where it has been suggested that remodeling is an active primary process that is at least partially independent of inflammation, perhaps even commencing in parallel with the inflammatory process .
One argument against the theory that remodeling is primarily the end-stage fibrosis resulting from an inflammatory process stems from study of the ultrastructure of the thickened subepithelial basement membrane as well as the timing of its formation. Basement membrane thickening is primarily the result of collagen deposition, which is a hallmark of the remodeling process in both upper and lower airways. In asthmatic bronchi, this thickening is due to deposition of reticulin fibers, mainly composed of collagen types III and V, which contrasts the prominence of type I fibrils in fibrosis and scar formation . The predominance of type III and V collagen has also been reported in mucosal remodeling in CRS . Another argument against remodeling being the end-product of inflammation is that the remodeling process is seen starting at an early age, with readily demonstrable thickened reticular basement membrane (RBM) in children with both mild and severe asthma [7–9]. It can be postulated that the effects of inflammation require more time to form such prominent RBM thickening. Further evidence suggesting against a temporal relationship between inflammation and remodeling in asthma was reported by Boulet et al. , who found that type I and type III collagen deposition beneath the basement membrane was similar in recently diagnosed and long-standing asthmatic patients, whereas Payne et al.  found that RBM thickness in children with asthma was not statistically different from that seen in adult asthmatic patients.
In contrast, review of the CRS literature supports the temporal aspect of remodeling. For instance, Rehl et al.  compared basement membrane thickness between control and CRS specimens. They found that diseased patients had thicker basement membranes. In addition, the thickness correlated positively with the duration of disease among diseased patients. Other studies [13–15] similarly found that features of remodeling such as basement membrane thickening and goblet cell hyperplasia were more prominent in adult CRS when compared with pediatric or adolescent CRS, lending further evidence for the temporal relationship that starts with inflammation and results in tissue remodeling.
Although existing evidence suggests that remodeling does not occur as a direct result of inflammation, it is still highly plausible that the two processes are strongly related. The primary regulator of the remodeling process is transforming growth factor beta (TGF-β), which induces fibroblast proliferation as well as differentiation of fibroblasts into myofibroblasts. These cells are responsible for deposition of collagen and other ECM components. The key source of TGF-β is inflammatory cells, most notably eosinophils [16,17], which are the main effector cells in asthma and CRS. The central role of eosinophils in remodeling has been further elucidated in studies of both interleukin 5 (IL-5)-deficient mice [18,19] and eosinophil-deficient mice . IL-5 is expressed by T cells, as well as eosinophils, and is important in eosinophil proliferation. These mice, unable to mount a proper eosinophilic response, were found to be protected from increased peribronchiolar collagen deposition and airway smooth muscle when compared with sham control mice [18,20].
Basement membrane thickness has also been reported to correlate with the density of underlying eosinophils both in sinusitis  and asthma . It is particularly interesting that features of mucosal remodeling in the sinuses have consistently been reported to be more prominent in those with comorbid asthma [12,23,24]. As CRS patients with asthma have higher eosinophilic load [23–26], it is inferred that remodeled mucosa is due to increased eosinophils and thus myofibroblasts and levels of TGF-β. This corresponds clinically, as asthmatic CRS patients have significantly increased TGF-β and myofibroblasts in sinus mucosa when compared with nonasthmatic individuals . Further evidence for a relationship between remodeling and inflammation is present in the distribution of TGF-β and myofibroblasts, which coincides with the increased concentration of eosinophils in the nasal polyp pedicle [27,28]. Eosinophils also produce IL-11 and IL-17, both having profibrotic effects [6,21] and positive correlation with epithelial damage and collagen deposition in the basement membrane [4,19].
Another proposed role of eosinophilic inflammation in the remodeling process is through alteration of balance between the matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). MMPs are involved in hydrolyzing components of the ECM and play a central role in tissue remodeling, whereas TIMPs inhibit metalloproteinase activity resulting in decreased ECM turnover. Therefore, a tipped MMP–TIMP balance results in accumulation of ECM proteins, which is seen clinically in formation of nasal polyps, especially when massive polyposis with aggressive recurrence are present. In fact, recurrence correlates positively with the eosinophilic load in the polyps [29,30▪]. Specifically, MMP-9 is thought to play an integral role (with TIMP-1) in tissue remodeling and has been positively associated with eosinophils [31–33]. MMP-9-positive cells were detected in increased numbers in pseudocyst formations in polyps , thus implicating MMP-9 in polyp core edema, with subsequent increased polyp size and potential accelerated polyp recurrence. This can be demonstrated in the aspirin-sensitive subgroup, which histologically exhibits higher grade mucosal eosinophilia than the aspirin-tolerant subgroup , and clinically presents with larger polyps, higher Lund–Mackay scores [35–37] and more aggressive recurrence [38▪,39,40]. In this subgroup, the MMP-9 : TIMP-1 ratio was found to be elevated (when compared with the aspirin-tolerant subgroup) [41▪], further supporting a role for MMPs and TIMPs in polyp growth and recurrence.
Another mechanism through which eosinophils can affect the remodeling process is through cysteinyl leukotrienes (CysLTs) [20,42,43]. The consistent overproduction of CysLTs (and their receptors) in the presence of aspirin sensitivity [44,45] could be an additional explanatory factor for the thicker subepithelial basement membrane found in this group . The role of CysLTs in remodeling has been demonstrated in mouse asthma models, wherein CysLT-1 receptor blockage caused suppression of the development of remodeling in the mucosa [43,46,47]. As mentioned previously, the prominence of CysLTs in the aspirin-sensitive population secondary to deranged eicosanoid metabolism, coupled with the diffuse polyposis and high recurrence rates occurring in these patients, suggests an implication of CysLTs in the mucosal remodeling process.
Despite the previous studies, the contribution of eosinophilic inflammation to the remodeling process is not straightforward. Baraldo et al.  compared eosinophilic with noneosinophilic asthmatic children and reported that remodeling occurred to a similar degree in both groups. This finding suggests that remodeling can occur even in the absence of prominent eosinophilia, thus indicating the involvement of other mechanisms . Further evidence for a remodeling pathway that does not rely as heavily on eosinophils is found in CRS. Tissue obtained from patients suffering from CRS with nasal polyps (CRSwNP) has been reported to have less collagen deposition and TGF-β despite higher loads of mucosal eosinophilia than CRS without polyps (CRSsNP) [49,50]. Remodeling also occurred consistently in nasal polyps of both western and Asian populations [50,51▪], despite different inflammatory profiles and generally lower levels of eosinophils in Asian sinusitis [52–54].
In summary, remodeling may not be a simple end-stage consequence of long-standing inflammation. However, parallel processes may occur with ongoing inflammation continuously contributing to remodeling. In tandem, remodeling can also contribute to inflammation, as fibroblasts release eosinophil chemoattractants such as eotaxins and regulated upon activation, normal T-cell expressed, and secreted (RANTES, also known as CCL-5) [55,56]. Although the effector cells and inflammatory pathways may differ, the role of cytokines in remodeling remains intriguing, and how this ultimately results in the similar clinical symptoms of sinusitis, irrespective of the underlying inflammatory profile.
Steroids are the mainstay of treatment in inflammatory airway disease, so it is important to investigate their effects on remodeling. Steroids have the theoretical potential to reverse remodeling through two primary means. The first is the ability to reverse pathologically remodeled airways by decreasing collagen deposition in the subepithelial basement membrane. The second possibility is that steroids delay or modify the remodeling process through anti-inflammatory actions. The former action has been frequently researched, mainly via assessment of collagen deposition. A number of these studies [10,57–59] (including two on sinus disease [6,60]) conclude that steroids do not effectively reverse collagen deposition (Table 2) [6,10,57–64]. This topic is not without debate, however, and other studies argue in favor of reversibility [61–64] (Table 2), though some suggest that reversibility may be attributable to high steroid dosage and long treatment duration . Although the latter (anti-inflammatory) action of steroids is well established, its impact on altering the course of remodeling and the specific clinical benefit of early intervention in this case have not been fully elucidated in CRS.
Exploiting different pathways, other medications have also been investigated in targeting remodeling. One such medication, mepolizumab (IL-5 antagonist), was administered via intravenous infusions to mild atopic asthmatic patients on β2-agonist therapy . The researchers found that the treated patients had reduced ECM protein deposition in the basement membrane in addition to decreased airway eosinophil numbers with lower TGF-β1 mRNA expression and lower concentration of TGF-β1 in bronchoalveolar lavage fluid . Another medication, montelukast, is a leukotriene antagonist that demonstrated in mouse asthma models that CysLT receptor blockade is capable of suppressing features of remodeling [43,46,47]. In addition, through targeting MMPs, doxycycline has been found in one study  to function comparably to oral steroids in decreasing nasal polyp size. Doxycycline's action is thought to occur through an inhibitory effect on MMP-9, eosinophil cationic protein (ECP), and myeloperoxidase . Future research is needed to further delineate the role of medications in inhibiting remodeling and inflammation.
Endoscopic surgery has become the standard practice for patients with CRSwNP and CRSsNP who remain symptomatic despite maximal medical therapy. The great clinical success achieved with FESS contributes to the belief that majority of pathologically remodeled mucosa is reversible to a more physiologic state. Improvement is seen grossly in sinuses postoperatively with decreased polyp burden, edema, and erythema; yet, less has been studied at a tissue level. In fact, contrary to surgical results, the limited available histological studies [67,68] suggest that despite clinical improvement, electron microscopy continues to demonstrate irreversible mucosal changes after surgery. Clinically, this failure of mucosa to revert to a normal state may be only evident in a small subset of patients who suffer from what some authors describe as a dysfunctional sinus or clinically irreversible sinus disease [69–72].
The ability of sinus mucosa to reverse pathologic changes could be a factor in determining the quality of recovery after surgery. Targeted therapy to prevent remodeling, therefore, has potential to improve postoperative outcomes. For example, poor healing after surgery has been linked to elevated levels of MMP-9 in nasal secretions preoperatively and postoperatively [82,83]. As inflammatory cells are the major source of MMP-9, residual leukocytes left in the sinuses during sinus surgery could be causative of poor mucosal recovery after surgery through the production of elevated levels of MMP-9. This supports the theory that surgery should aim at reducing the pathologic tissue and thus inflammatory load [84▪]. In line with this thought process, Huvenne et al.  studied the effects of doxycycline as an anti-MMP-9 therapy in the form of doxycycline-bearing stents in postoperative patients. In this pilot study , improved healing quality was suggested based on endoscopic evaluation. Similarly, evidence suggests that chitosan gel improves wound healing and reduces adhesions after sinus surgery [86,87]. One explanation for the benefits of chitosan is that chitin derivatives like chitosan inhibit MMP-2 and MMP-9 [88,89]. Adjunct therapies to surgery could thus have positive effects to encourage reversal of pathologically remodeled mucosa and should remain an active area for research.
The relationship between inflammation and remodeling in CRS is a complex one and not yet completely understood. Recent evidence suggests mucosal remodeling is an active and complex process that is not necessarily an unavoidable fibrotic consequence of continued inflammation. In CRS, as well as asthma, the relationship between inflammation and remodeling is a complex one involving a multitude of overlapping pathways. The wide array of cellular and cytokine players include neutrophils, eosinophils, various interleukins, TGF-β, MMPs, TIMPs, and CysLTs, just to name a few. Interestingly, similar structural changes have been demonstrated regardless of the prevailing underlying inflammatory profile [51▪]. The complexity of the inflammatory profiles in all likelihood reflects the underlying heterogeneity of the different ‘endotypes’ of inflammatory airway disease [90–92].
With the strong link between inflammation and remodeling, anti-inflammatory medications (topical steroids being the gold standard) have the potential to delay the onset of remodeling and alter the course of the disease. However, studies suggest that anti-inflammatory approaches alone are not successful in reversing changes such as collagen deposition, indicating that early treatment might be crucial for preventing disease progression. Novel antieosinophilic treatments such as IL-5 antagonists and leukotriene antagonists may exhibit additional benefit in controlling the disease, especially in patients with high eosinophilic loads. Anti-MMP therapy also possesses the potential to modify healing quality after surgery and influence matrix deposition, which may prove important in tempering polyp growth and recurrence. Future studies are needed to discern the efficacy and indications for these medical interventions.
Surgery is a treatment option applicable to the sinonasal passages, which is not available to address diseased bronchial mucosa, and surgery has demonstrated benefit in those who fail medical therapy for CRS. Due to remodeled mucosa, the conservative philosophy of FESS and minimally invasive sinus technique to relieve ostial obstruction is very likely insufficient in handling severe disease states with high inflammatory loads and/or a dysfunctional mucosa (Fig. 1). These patients derive more benefit from maximal surgical options directed toward eliminating the inflammatory load and improving access for topical medication to retard or reverse the mucosal damage. Additionally, removal of irreversibly diseased mucosa allows healthy mucosa to regenerate in its place . Due to the complexity of disease in recalcitrant sinusitis, it is likely that multimodality treatment will serve these patients best.
Papers of particular interest, published within the annual period of review, have been highlighted as:
Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 119).
1. Lazarus S. Mild persistent asthma: is any treatment needed? J Allergy Clin Immunol 2006; 118:805–808.
2. Bachert C, Patou J, Van Cauwenberge P. The role of sinus disease in asthma. Curr Opin Allergy Clin Immunol 2006; 6:29–36.
3. Ponikau JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis
: is the histopathology similar to asthma? J Allergy Clin Immunol 2003; 112:877–882.
4. Bush A. How early do airway inflammation and remodeling occur? Allergol Int 2008; 57:11–19.
5. Saglani S, Molyneux C, Gong H, et al. Ultrastructure of the reticular basement membrane in asthmatic adults, children and infants. Eur Respir J 2006; 28:505–512.
6. Molet SM, Hamid QA, Hamilos DL. IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate. Laryngoscope 2003; 113:1803–1812.
7. Barbato A, Turato G, Baraldo S, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med 2003; 168:798–803.
8. Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol 2012; 129:974–982.e13.
9. Saglani S, Payne DN, Zhu J, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med 2007; 176:858–864.
10. Boulet LP, Turcotte H, Laviolette M, et al. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma: influence of inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162 (4 Pt 1):1308–1313.
11. Payne DNR, Rogers AV, Adelroth E, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003; 167:78–82.
12. Rehl RM, Balla AA, Cabay RJ, et al. Mucosal remodeling
in chronic rhinosinusitis
. Am J Rhinol 2007; 21:651–657.
13. Sobol SE, Fukakusa M, Christodoulopoulos P, et al. Inflammation and remodeling of the sinus mucosa in children and adults with chronic sinusitis. Laryngoscope 2003; 113:410–414.
14. Chan KH, Abzug MJ, Coffinet L. Chronic rhinosinusitis
in young children differs from adults: a histopathology study. J Pediatr 2004; 144:206–212.
15. Zang H-R, Wang T, Li Y-C, et al. A histopathological study: chronic rhinosinusitis
in adolescents versus adults. Zhonghua Yi Xue Za Zhi 2009; 89:1975–1978.
16. Ohno I, Lea RG, Flanders KC, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest 1992; 89:1662–1668.
17. Eisma RJ, Allen JS, Lafreniere D, et al. Eosinophil expression of transforming growth factor-beta and its receptors in nasal polyposis: role of the cytokines in this disease process. Am J Otolaryngol 1997; 18:405–411.
18. Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004; 113:551–560.
19. Tanaka H, Komai M, Nagao K, et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 2004; 31:62–68.
20. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305:1776–1779.
21. Saitoh T, Kusunoki T, Yao T, et al. Relationship between epithelial damage or basement membrane thickness and eosinophilic infiltration in nasal polyps with chronic rhinosinusitis
. Rhinology 2009; 47:275–279.
22. Ward C, Reid DW, Orsida BE, et al. Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma: a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy 2005; 35:1565–1571.
23. Dhong H-J, Kim HY, Cho D-Y. Histopathologic characteristics of chronic sinusitis with bronchial asthma. Acta Otolaryngol 2005; 125:169–176.
24. Ardehali MM, Amali A, Bakhshaee M, et al. The comparison of histopathological characteristics of polyps in asthmatic and nonasthmatic patients. Otolaryngol Head Neck Surg 2009; 140:748–751.
25. Jankowski R, Bouchoua F, Coffinet L, Vignaud JM. Clinical factors influencing the eosinophil infiltration of nasal polyps. Rhinology 2002; 40:173–178.
26. Haruna S, Nakanishi M, Otori N, Moriyama H. Histopathological features of nasal polyps with asthma association: an immunohistochemical study. Am J Rhinol 2004; 18:165–172.
27. Wang QP, Escudier E, Roudot-Thoraval F, et al. Myofibroblast accumulation induced by transforming growth factor-beta is involved in the pathogenesis of nasal polyps. Laryngoscope 1997; 107:926–931.
28. Min YG, Kim YJ, Yun YS. Distribution of eosinophil granule proteins in nasal mucosa of atopic patients with nasal polyposis. ORL J Otorhinolaryngol Relat Spec 1996; 58:82–86.
29. Tosun F, Arslan HH, Karslioglu Y, et al. Relationship between postoperative recurrence rate and eosinophil density of nasal polyps. Ann Otol Rhinol Laryngol 2010; 119:455–459.
30▪. Nakayama T, Yoshikawa M, Asaka D, et al. Mucosal eosinophilia and recurrence of nasal polyps: new classification of chronic rhinosinusitis
. Rhinology 2011; 49:392–396.
This study indicates the importance of the eosinophilic inflammatory load in determining surgical prognosis.
31. Ohno I, Ohtani H, Nitta Y, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997; 16:212–219.
32. Hoshino M, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998; 102:783–788.
33. Schwingshackl A, Duszyk M, Brown N, Moqbel R. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. J Allergy Clin Immunol 1999; 104:983–989.
34. Watelet JB, Bachert C, Claeys C, Van Cauwenberge P. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs nasal polyposis. Allergy 2004; 59:54–60.
35. Mascia K, Borish L, Patrie J, et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005; 94:652–657.
36. Robinson JL, Griest S, James KE, Smith TL. Impact of aspirin intolerance on outcomes of sinus surgery. Laryngoscope 2007; 117:825–830.
37. Awad OG, Fasano MB, Lee JH, Graham SM. Asthma outcomes after endoscopic sinus surgery
in aspirin-tolerant versus aspirin-induced asthmatic patients. Am J Rhinol 2008; 22:197–203.
38▪. Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. Revision rates after endoscopic sinus surgery
: a recurrence analysis. Ann Otol Rhinol Laryngol 2011; 120:162–166.
This study shows that asthma and aspirin intolerance are important clinical factors determining the aggressiveness of recurrence.
39. Albu S, Tomescu E, Mexca Z, et al. Recurrence rates in endonasal surgery for polyposis. Acta Otorhinolaryngol Belg 2004; 58:79–86.
40. Bassiouni A, Wormald P-J. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope (in press).
41▪. Mudd PA, Katial RK, Alam R, et al. Variations in expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in nasal mucosa of aspirin-sensitive versus aspirin-tolerant patients with nasal polyposis. Ann Allergy Asthma Immunol 2011; 107:353–359.
The findings of this study suggest indirectly, through the aspirin intolerance variable, a role for MMPs (and their inhibitors) in polyp growth and recurrence.
42. Steinke JW, Bradley D, Arango P, et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol 2003; 111:342–349.
43. Kiwamoto T, Ishii Y, Morishima Y, et al. Blockade of cysteinyl leukotriene-1 receptors suppresses airway remodelling in mice overexpressing GATA-3. Clin Exp Allergy 2011; 41:116–128.
44. Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis
. J Allergy Clin Immunol 2005; 115:316–322.
45. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493–1499.
46. Henderson WR Jr, Chiang GKS, Tien Y-T, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173:718–728.
47. Muz MH, Deveci F, Bulut Y, et al. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp Mol Med 2006; 38:109–118.
48. Baraldo S, Turato G, Bazzan E, et al. Noneosinophilic asthma in children: relation with airway remodelling. Eur Respir J 2011; 38:575–583.
49. Van Bruaene N, Derycke L, Perez-Novo CA, et al. TGF-beta signaling and collagen deposition in chronic rhinosinusitis
. J Allergy Clin Immunol 2009; 124:253–259.259.e1-2.
50. Li X, Meng J, Qiao X, et al. Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis
. J Allergy Clin Immunol 2010; 125:1061–1068.
51▪. Van Bruaene N, Bachert C. Tissue remodeling in chronic rhinosinusitis
. Curr Opin Allergy Clin Immunol 2011; 11:8–11.
An important conclusion of the authors is that a form of remodeling seems to always occur, regardless of the underlying inflammatory phenotype, suggesting that remodeling is more consistent than the inflammatory patterns.
52. Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008; 122:961–968.
53. Shi J, Fan Y, Xu R, et al. Characterizing T-cell phenotypes in nasal polyposis in Chinese patients. J Investig Allergol Clin Immunol 2009; 19:276–282.
54. Cao P-P, Li H-B, Wang B-F, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis
in adult Chinese. J Allergy Clin Immunol 2009; 124:478–484.484.e1-2.
55. Nonaka M, Pawankar R, Saji F, Yagi T. Eotaxin synthesis by nasal polyp fibroblasts. Acta Otolaryngol 1999; 119:816–820.
56. Saji F, Nonaka M, Pawankar R. Expression of RANTES by IL-1 beta and TNF-alpha stimulated nasal polyp fibroblasts. Auris Nasus Larynx 2000; 27:247–252.
57. Chakir J, Shannon J, Molet S, et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 2003; 111:1293–1298.
58. Baraket M, Oliver BGG, Burgess JK, et al. Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study. Respir Res 2012; 13:11.
59. Chakir J, Loubaki L, Laviolette M, et al. Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study. Eur Respir J 2010; 35:48–53.
60. Mastruzzo C, Greco LR, Nakano K, et al. Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic upper airway inflammation. J Allergy Clin Immunol 2003; 112:37–44.
61. Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57:309–316.
62. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864–1871.
63. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150:17–22.
64. Hoshino M, Nakamura Y, Sim JJ, et al. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy 1998; 28:568–577.
65. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029–1036.
66. Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol 2010; 125:1069–1076.e4.
67. Toskala E, Rautiainen M. Electron microscopy assessment of the recovery of sinus mucosa after sinus surgery. Acta Otolaryngol 2003; 123:954–959.
68. Thiele A, Holzhausen H-J, Riederer A, Knipping S. Mucosal remodeling
in chronic rhinosinusitis
without nasal polyposis: an ultrastructural evaluation. Laryngorhinootologie 2010; 89:352–357.
69. Richtsmeier WJ. Top 10 reasons for endoscopic maxillary sinus surgery failure. Laryngoscope 2001; 111 (11 Pt 1):1952–1956.
70. Cho D-Y, Hwang PH. Results of endoscopic maxillary mega-antrostomy in recalcitrant maxillary sinusitis. Am J Rhinol 2008; 22:658–662.
71. Cutler JL, Duncavage JA, Matheny K, et al. Results of Caldwell–Luc after failed endoscopic middle meatus antrostomy in patients with chronic sinusitis. Laryngoscope 2003; 113:2148–2150.
72. Kikawada T, Nonoda T, Matsumoto M, et al. Treatment of intractable diseased tissue in the maxillary sinus after endoscopic sinus surgery
with high-pressure water jet and preservation of the periosteum. Arch Otolaryngol Head Neck Surg 2000; 126:55–61.
73. Bassiouni A, Naidoo Y, Wormald P-J. Does mucosal remodeling
in chronic rhinosinusitis
result in irreversible mucosal disease
? Laryngoscope 2012; 122:225–229.
74. Schlosser RJ. Surgical salvage for the nonfunctioning sinus. Otolaryngol Clin North Am 2010; 43:591–604.ix–x.
75. Ragheb S, Duncavage JA. Maxillary sinusitis: value of endoscopic middle meatus antrostomy versus Caldwell–Luc procedure. Operat Tech Otolaryngol Head Neck Surg 1992; 3:129–133.
76. Sathananthar S, Nagaonkar S, Paleri V, et al. Canine fossa puncture and clearance of the maxillary sinus for the severely diseased maxillary sinus. Laryngoscope 2005; 115:1026–1029.
77. Seiberling K, Ooi E, MiinYip J, Wormald P-J. Canine fossa trephine for the severely diseased maxillary sinus. Am J Rhinol Allergy 2009; 23:615–618.
78. Gross WE, Gross CW, Becker D, et al. Modified transnasal endoscopic Lothrop procedure as an alternative to frontal sinus obliteration. Otolaryngol Head Neck Surg 1995; 113:427–434.
79. Wormald PJ. Salvage frontal sinus surgery: the endoscopic modified Lothrop procedure. Laryngoscope 2003; 113:276–283.
80. McFadden EA, Kany RJ, Fink JN, Toohill RJ. Surgery for sinusitis and aspirin triad. Laryngoscope 1990; 100 (10 Pt 1):1043–1046.
81. Seiberling KA, Church CA, Tewfik M, et al. Canine fossa trephine is a beneficial procedure in patients with Samter's triad. Rhinology 2012; 50:104–108.
82. Watelet J-B, Claeys C, Cauwenberge PV, Bachert C. Predictive and monitoring value of matrix metalloproteinase-9 for healing quality after sinus surgery. Wound Repair Regen 2004; 12:412–418.
83. Watelet JB, Demetter P, Claeys C, et al. Neutrophil-derived metalloproteinase-9 predicts healing quality after sinus surgery. Laryngoscope 2005; 115:56–61.
84▪. Bassiouni A, Naidoo Y, Wormald P-J. When FESS fails: the inflammatory load hypothesis in refractory chronic rhinosinusitis
. Laryngoscope 2012; 122:460–466.
This report suggests that surgery can successfully address the inflammatory load in the mucosa.
85. Huvenne W, Zhang N, Tijsma E, et al. Pilot study using doxycycline-releasing stents to ameliorate postoperative healing quality after sinus surgery. Wound Repair Regen 2008; 16:757–767.
86. Athanasiadis T, Beule AG, Robinson BH, et al. Effects of a novel chitosan gel on mucosal wound healing following endoscopic sinus surgery
in a sheep model of chronic rhinosinusitis
. Laryngoscope 2008; 118:1088–1094.
87. Valentine R, Athanasiadis T, Moratti S, et al. The efficacy of a novel chitosan gel on hemostasis and wound healing after endoscopic sinus surgery
. Am J Rhinol Allergy 2010; 24:70–75.
88. Rajapakse N, Kim M-M, Mendis E, et al. Carboxylated chitooligosaccharides (CCOS) inhibit MMP-9 expression in human fibrosarcoma cells via down-regulation of AP-1. Biochim Biophys Acta 2006; 1760:1780–1788.
89. Kim M-M, Kim S-K. Chitooligosaccharides inhibit activation and expression of matrix metalloproteinase-2 in human dermal fibroblasts. FEBS Lett 2006; 580:2661–2666.
90. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107–1119.
91. Huvenne W, van Bruaene N, Zhang N, et al. Chronic rhinosinusitis
with and without nasal polyps: what is the difference? Curr Allergy Asthma Rep 2009; 9:213–220.
92. Pawankar R, Nonaka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis
and nasal polyps. Curr Allergy Asthma Rep 2007; 7:202–208.